Xiaoxue Zha

Single-cell multiomics identifies an ALDH9A1–carnitine signaling axis driving resistance of NSCLC to immunotherapy

Significance Although immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of non–small cell lung cancers (NSCLCs), majority of patients ultimately develop primary or acquired resistance, limiting long-term therapeutic benefits. Here, we show that ALDH9A1, the committed enzyme in carnitine bi...